Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth

Ka-Won Noh1,* Jihyun Park1,* & Myung-Soo Kang1,2,3,*

1Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, 2Samsung Biomedical Research Institute (SBRI), Samsung Medical Center, Seoul 06351, 3BioMembrane Plasticity Research Center (MPRC), Seoul National University College of Medicine, Seoul 03080, Korea

Epstein Barr virus (EBV)-encoded nuclear antigen-1 (EBNA1) plays a pivotal in an EBV episome replication and persistence. Despite considerable attempts, there are no EBV drugs or vaccines. We attempted to eradicate EBV episomes by targeting EBNA1 using the transcription activator-like effector nucleases (TALEN). E1TN-mediated transient knockout (KO) of EBNA1 reduced EBNA1 expression, and caused significant loss of EBV genomes and progressive death of EBV-infected cells. Furthermore, when a mixture of EBV-infected Burkitt’s lymphoma (BL) cells and EBV-negative BL cells was targeted by E1TN, EBV-negative cells were counter-selected while most EBV-infected cells died, further substantiating that EBNA1 KO caused selective death of EBV-infected cells. TALEN-mediated transient targeting of EBNA1 attenuated the growth of EBV-infected cells, implicating a possible therapeutic application of E1TN for EBV-associated disorders. [BMB Reports 2016; 49(4): 226-231]

INTRODUCTION

Epstein-Barr virus (EBV) establishes lifelong latency in its hosts by undergoing latent replication and persistence of viral episomal genomes. EBV infection is considered a high risk factor for > 1% of all human cancers (1). Although the synthesis of viral genome is initiated by the host replication machinery, efficient replication and long term persistence require EB nuclear antigen 1 (EBNA1)-mediated DNA binding activity (2). In latent infections, including malignancies, EBV usually persists as a multi-copy episome (3, 4). EBV genome integration is unusual (5, 6). EBNA1 is essential for EBV genome replication and persistence and that EBV genome endures specific genomic sites (13). Despite considerable attempts to develop EBV drugs or vaccines (16). Thus, we have attempted to target EBNA1 in living cells by using TALEN system (E1TN) to assess the potential therapeutic effect of E1TN on the growth of EBV-infected gastric cancer (GC), Burkitt’s lymphoma (BL), and lymphoblastoid cell line (LCL) (13, 17-19).

RESULTS

Transient EBNA1 KO caused selective cell death in EBV-infected cells

Given that EBNA1 is essential for EBV extra-chromosomal genome replication and persistence and that EBV genome endurance is usually required for EBV-infected cell growth, we hypothesized that targeted transient disruption of EBNA1 by E1TN pair will cause a selective death or attenuation of EBV-infected cells but not EBV-negatives in vitro. To this end, we transiently targeted EBNA1 by transfecting EBV-infected cells (therefore EBNA1-positive) with pair of EBNA1 targeting E1TN vectors and surrogate EBNA1 marker reporter of red fluorescence protein / green fluorescence protein (RFP / GFP (EBNA1)) at 1:1:2 ratio, sorted double negative and double positive for RFP/GFP, plated in a 96-well plate at various densities (1, 10, 20, 50, 100, 200, 500 cells per well depending on cell types), and scored the number of wells where cells outgrew at 2 weeks post plating (Table S1, Fig. 1A, B). Those RFP / GFP cells were assumed to have gone through E1TN pair-induced frame shift mutation(s) on targeting site in surrogate RFP / GFP reporter plasmid constitutively expresses RFP when the GFP sequence is bound to the RFP sequence out of frame. GFP expression is recovered by EBV episome persistence in dividing cells and enhances episome transcription (7, 8), validating the status of EBNA1 as a reasonable target protein for the treatment of EBV-associated diseases (9-12). EBV genome has 24 cognate sites in OriP element where EBNA1 binds, enabling EBV genome replication and transcription. Transcription activator-like effector (TALE)-based nuclease (TALEN) can introduce frame-shift mutation in specific genomic sites (13). Despite considerable efforts towards developing EBV drugs (9, 14, 15), there is no FDA-approved EBV drugs or vaccines (16). Thus, we have attempted to target EBNA1 in living cells by using TALEN system (E1TN) to assess the potential therapeutic effect of E1TN on the growth of EBV-infected gastric cancer (GC), Burkitt’s lymphoma (BL), and lymphoblastoid cell line (LCL) (13, 17-19).

Keywords: Cell death, EBNA1, Epstein-Barr Virus, Knockout, TALEN

*Corresponding author. Tel: +82-2-740-8919; Fax: +82-2-740-8918; E-mail: emeskang@gmail.com

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
EBNA1 disruption attenuated EBV+ cell growth
Ka-Won Noh, et al.

Fig. 1. Transient knock-out (KO) of EBNA1 in EBV-infected cancer cells caused substantial cell death. (A) Experimental scheme of TALEN-mediated KO of EBNA1. RFP/GFP double positive cells were sorted by FACS at 48 hr-post transfection and plated in 96 well plates at various cell densities of 1, 10, 100, 1000 cells/well. Three weeks after plating, the number of outgrown wells was scored. (B) Approximately 6.1% and 3.4% cells showed double positivity in EBNA1-targeted RAJI E1TN and SNU-719 E1TN cells. The percentage of strong RFP+GFP+ cells was usually less than that observed by the fluorescent microscope. (C) Single transfection of the E1TN pair induced a death of EBV-positive RAJI Burkitt’s lymphoma (BL), SNU-719 gastric carcinoma (GC) and SNU-265 lymphoblastoid cell line (LCL) cells but not in EBV-negative BJAB BL cells. Double-positive or double-negative cells were plated at 10 cells of BJAB per well or 100 cells of SNU-719 and SNU-265 per wells for SNU-719 and SNU-265. E1TN pair did not show significant toxicity as observed from similar cell plating efficiency. E1TN pair mediated transient KO of EBNA1 in EBV-infected RAJI BL and SNU-719 GC cell line induced progressive cell death. P value by Student’s t-test (*P < .0001). (D) Second transfection of E1TN pair resulted in a significant decrease in the plating efficiency of RAJI cells, likely inducing progressive cell death. Upon first round of transfection (denoted as 1 in the number of E1TN pair transfection), all double negative cells (non-transfected) grew rapidly while double positive cells died at a rate of 20%. Upon second and third rounds of transfections into selected and outgrown colonies of RAJI cells from the first round, cells in most wells (85% and 95%, respectively) died when plated at a density of 100 cells/well.

Frame shift mutation via error-prone non homologous end joining (NHEJ) only when the potential target site is disrupted.

In support of the hypotheses, plating RFP+/GFP+ RAJI at 1, 10, and 100 cells/well upon EBNA1 transient disruption resulted in 100, 68, and 20% of cell death, respectively. In contrast, plating the RFP−/GFP− RAJI BL control fraction at 1, 10 and 100 cells/well gave rise to 90, 28, 0% of cell death in total wells, respectively, as expected; this was indicative of the significantly higher rate of cell death in EBNA1-targeted cells (RFP+/GFP+) than in EBNA1-non-targeted cells (RFP−/GFP−) (P < .0001) (Fig. 1C, D, Table S1). The effect was even more striking in the adherent SNU-719 cells, a naturally EBV-infected GC cell line, as plating RFP+/GFP+ cells at less than or equal to 100 cells per well resulted in no or almost no outgrowth. For 500 cells/well, only 20% grew from all the wells (Table S1, Fig. 1C). We have observed essentially similar results from the SNU-265 cell line, a naturally EBV infected LCL; Plating of EBNA1-targeted, hence RFP+/GFP+, SNU-265 LCL cells at a density of < 50 cells/well gave rise to no outgrowth. The possibility that E1TN pair is toxic to cells was ruled out in the experiment using EBV-negative BJAB cells. Transfection of the E1TN pair into BJAB BL (hence EBNA1-negative) did not affect cell growth in the aforementioned experiment (Table S1, Fig. 1C). These results indicate that E1TN-mediated transient KO of EBNA1 in EBV-infected cells is sufficient for the attenuation or death of EBV-positive cells with no discernible toxicity.

Repeated, transient transfection of E1TN pair induced progressive EBV+ RAJI cell death and transient EBNA1 KO caused decrease in EBNA1 level and EBV genome copy number

To substantiate the negative role of E1TN pair in EBV-infected cell growth, RFP/GFP double positive cells from the first transfected RAJI were grown until all cells were verified to no longer carry E1TN by fluorescence-activated cell sorting (FACS) analyses (note that the reporter plasmid and E1TN pair plasmids do not carry antibiotics-resistance markers). The sub-populations were brought up transfected, plated at a density of 300 cells/well in 96-well plate, and scored for cell survival as described above during 2 weeks post plating. As a result, further KO by the second transfection of E1TN resulted in progressive cell death in 87 of 96 wells (Table S2, Fig. 1D). Western blotting analyses to EBNA1 monoclonal antibody verified the decrease in EBNA1 from first (Fig. 2A, B, single transfection) and successive second rounds of E1TN pair transfection (Fig. 2C, 3 rounds of transfection) in type III latent RAJI and type I latent SNU-719, both of which are naturally EBV-infected cancer cells. In RAJI cells showing type III EBV latency in which EBNA2 and LMP1 are also expressed from episomal
EBNA1 disruption attenuated EBV+ cell growth
Ka-Won Noh, et al.

Fig. 2. Repeated, transient transfection of E1TN pair caused the decrease in EBNA1 level and growth attenuation of EBV-infected cells. (A, B) Western blotting (WB) to EBNA1, EBNA2, LMP1 and β-actin in the clones (shown in Fig. 1C or D) of RAJI cells with type III latency (A) and to EBNA1 in SNU-719 cells with type I latency (B). Note there was more robust knock-down (KD) in EBNA1 by the second round (E1TNx2) than by the first round targeting (E1TNx1) in both RAJI and SNU-719. The relative cell growth (RCG) of EBV low (therefore EBNA1 low) clones was typically between 10% and at most 50% in vitro (denoted as .1 to .5) (see RCG). (C) Third round and repeated transfection of E1TN (RAJIE1TNx3) caused more significant, but incomplete, loss of EBNA1. Note the low expression of EBNA2 and LMP1 in RAJI in panel A and C likely results from unusual experimental deviation. (D) The target region of EBNA1 was PCR-amplified, denatured, annealed, and digested with T7 endonuclease 1 (T7E1). The appearance of shorter bands or disappearance of expected DNA bands indicates E1TN pair-mediated occurrence of deletion or frame-shift mutation in the target site of EBNA1. (E) In vitro cell growth attenuation in EBNA1 low cells (RAJI E1TN8, RAJIE1TN11) and SNU-719E1TN4 SNU-719E1TN9 compared to their parental cells (RAJI PT, SNU-719PT). EBV genomes, EBNA1 targeting resulted in concomitant decrease in the EBNA2 but less robustly in LMP1 (Fig. 2A, C). Surviving colonies (RAJIE1TN5, SNU-719E1TN5) were verified to have a “cut and rejoin in the target site”, which likely resulted from a frame shift event as shown by T7E1 assay (Fig. 2D); therefore, lower level of EBNA1 was noted. Although insertion or deletions (indels) cannot be observed with the naked eye, the faded bands after T7E1 treatment imply that TALEN worked and did partially delete EBNA1. RAJIE1TN5 cells were further propagated, re-transfected, plated at 300 cells/well in 96-well plate, and scored for cell survival in 2 weeks after plating in the same way. This repeated KO of EBNA1 then again induced progressive cell death in 96% of wells. However, ultimately no derivation of EBV-elminated RAJI cells suggests that the persistence of EBV episome by the virtue of functional EBNA1 is essential for prolonged growth of EBV-infected cells in vitro (Table S2). EBNA1 expression was significantly lower in several clones that survived from multiple rounds of E1TN pair transfection (RAJIE1TN, Fig. 2A and SNU-719E1TN in Fig. 2B). In accordance with the hypothesis, E1TN-targeted EBV low (therefore EBNA1 low) clones grew at a much slower rate between 10% and 50% in vitro (Fig. 2A, B, see the relative cell growth (RCG) under panel pictures).

EBNA1 KO counter-selected EBV-negative cells from the pre-mixtures of EBV-negative and EBV-infected cells
The failure to derive EBV-elminated yet live cells validates the requirement of EBV genome for cell growth and survival. Therefore, we performed spike experiments in an attempt to check whether transient EBNA1 KO can counter select EBV-negative cells from a mixture of EBV-negative and infected cells. To support this idea, we premixed EBV-negative BJAB and EBV-infected RAJI cells at 1:100, 10:1 and 10 ratios, which were then followed by the transfection of RFP +/GFP + EBNA1 reporter and E1TN pair in the same method as mentioned in Fig. 3A. These resulting surviving clones were propagated and 12 randomly selected clones were subjected to FGA short tandem repeat analyses using BJAB and RAJI as the references. As a result, the higher number of spiked BJAB cells, the more BJAB cells were counter-selected (Table S3, Fig. 3B); Two, six and nine clones of 12 randomly selected clones from 1:1000, 1:100 and 1:10 spiked ratio, respectively, were identified as BJAB cells. A spike ration of 1:1000 of BJAB: RAJI induced the survival ratio of 84 from 88 wells and short tandem repeats (STR) analyses for randomly selected 12 colonies revealed 2 BJAB cell line (Table S3) (STR data not shown). In the next spiking experiment where 10-fold BJAB cells were premixed with RAJI cells (BJAB: RAJI at 1:100 ratio), 23 of 30 wells were selected (77%) and STR analyses for randomly selected 12 colonies verified that a higher number of BJAB (6/12, 50%), and a concomitantly less number of RAJI (5/12, 42%) cells, were selected as expected (Fig. 3C). Identity was further verified by comprehensive STR analyses using 16 markers (Fig. 3D). Furthermore, spiking of BJAB with RAJI cells at a ratio of 1:10
EBNA1 disruption attenuated EBV+ cell growth
Ka-Won Noh, et al.

Fig. 3. Transient KO of EBNA1 in spiked cells counter-selected most EBV-negative BJAB cells. (A) Experimental scheme of TALEN-mediated KO of EBNA1. EBV-negative BJAB and EBV-infected RAJI cells were mixed at a ratio of 1:3×10^3, transiently transfected, sorted, and selected as described above. (B) Higher counter-selection of EBV-negative BJAB cells from the cell mixture with higher BJAB to RAJI ratio. (C, D) Western blotting analysis to EBNA1 and beta-actin antibody and short tandem repeat (STR) analyses (D) for the randomly selected 12 clones from the 1:100 BJAB:RAJI spiked experiment. WB revealed that two clones (clone 3 and 10) were RAJI cells and therefore these two were not subjected to STR.

resulted in partial growth in 52 wells out of 96 plated wells. STR analysis of randomly selected 12 wells showed that majority of the survived colonies (9/12, 75%) were BJAB cells and only 2 of them (2/12, 17%) were RAJI with significant EBNA1 KD shown (Table S3, Fig. 4A, B). Their identities were further verified by comprehensive STR analyses using 16 markers.
EBNA1 disruption attenuated EBV^+ cell growth
Ka-Won Noh, et al.

One representative clone (BJAB:RAJI E1TN-selected-1 [BJRJST-1]) was presumed to be BJAB from the STR. As presumed, this clone was found to be BJAB from the comprehensive STR analyses (Fig. 4C). In addition, EBV negativity in BJRJST-1 was shown through EBER in situ staining (Fig. 4D). EBNA1 KD was collinear to EBNA2 and LMP1 KD in representative clones (Fig. 3E). These spike experiments indicate that transient EBNA1 KO can selectively attenuate EBV-infected cells and counter select more EBV-negative cells in vitro via selectively targeting EBV^+ RAJI cells.

**E1TN induced progressive loss of EBV episome from EBV-infected BL cells**

We next attempted to determine the efficiency of E1TN pair to eliminate EBV episomes from the transformed BL cells whose growth depends on the presence of EBV. In support of this idea (20), we infected BJAB cells with green EBV BAC virus, in which the GFP represents the existence of EBV episome persistence. We then transfected RFP^+GFP^−EBNA1 reporter into BJAB-EBV^+ cells along with or without the E1TN pair. The RFP^+GFP^− cells were FACs-sorted and plated, and the EBV^GFP^− cell fraction was determined by flow cytometry. Single transient transfection of E1TN pair induced progressive loss of EBV episome from the EBV-infected BJAB BL cells (Fig. 4F). The progressive loss of EBV was presented with GFP (Note that transient single transfection induced EBV loss by 39% to 32% over 2 weeks upon transient KD of EBNA and the cells were not subjected to selection, as the E1TN pair carries no antibiotics resistance markers).

**DISCUSSION**

We attempted to eradicate EBV episome from EBV-infected GC, BL, and LCL cells by targeting EBNA1, an essential protein for latent viral replication and persistence. Our results showed that targeted transient disruption of EBNA1 by E1TN could induce selective death of naturally EBV-infected cells, but not EBV-negative cells, thereby resulting in no derivation of EBV-eliminated daughter cells from EBV-infected parental cells. These results strongly support the hypothesis that EBNA1-mediated EBV latent episome persistence is necessary for persistent growth of EBV-infected cells. The requirement of EBNA1 for EBV persistence was further substantiated in the subsequent spike experiments; the pre-mixture of EBV-infected BJAB cells and subsequent targeted transient disruption of EBNA1 counter-selected mostly EBV-negative BJAB cells.

Knocking out multiple alleles of EBNA1 that are likely present in polyplody cells would be highly difficult. Therefore, we have attempted multiple rounds of KO by repeated transfection of the E1TN pair. However, this was inadequate to claim any negative derivatives. From multiple rounds of E1TN pair transfection into several different EBV-infected cell lines in this study, more than 14 RAJI colonies managed to grow but none of them showed complete lack of EBV episomes or knockout of EBNA1, suggesting that cell death is followed by EBNA1 KO, because of the defects in EBV genome replication or persistence. Similar results were observed in SNU-265 and SNU-719 cells, supporting that whichever cells containing nuclease-induced mutations most likely died out.

To the best of our knowledge, this is the first report that TALEN-mediated transient targeting of EBNA1 can efficiently attenuate the growth of EBV-infected cells, implicating possible therapeutic application of E1TN when the E1TN pair was effectively delivered by concentrated nasal spray containing E1TN, in particularly to the nasopharyngeal epithelial mucosa in nasopharyngeal carcinoma patients. Because a TALEN system requires two TALEN vectors, use of lentivirus or adenovirus is not feasible to deliver two TALEN vectors in a single viral vector which has a small maximum cloning capacity. In summary, transient targeted disruption of EBNA1 induced death and growth attenuation of EBV-infected cells.

**MATERIALS AND METHODS**

**EBNA1 TALEN design**

To disrupt EBNA1, two EBNA1_TALEN nucleases (E1TN_L1 and E1TN_R1) were constructed: E1TN_L1 and E1TN_R1 recognize EBNA1 nucleotide (nt) 41 to 59 from the start codon and nt 72 to 90, respectively. Six different DNA binding domain (DBD) modules each of which recognizes 3 bases from the EBNA1 sequence nt 41 to 59 were selected, arrayed, and fused to the catalytic domain of type II restriction enzyme FokI to induce specific cleavage of EBNA1 site (E1TN_L1). Similarly, 6 additional DBD modules that recognize 3 bases each from the nt 72 to 90 were fused to FokI as well (E1TN_R1) (17, 18). Additionally, a RFP^+GFP^−EBNA1 reporter plasmid that harbors two reporter genes (constitutively expressing the monomeric red fluorescence protein (RFP) open reading frame (ORF) and conditionally expressing the inducible enhanced green fluorescence protein (EGFP) ORF) with the target site (EBNA1 nt 40 to 90) fused to the GFP ORF out-of-frame was constructed. Constitutive RFP indicates transfection efficiency while EGFP expression implies that a potential target site was disrupted. EGFP only becomes expressed when the E1TN pair mediates in-frame correction from the out-of-frame site at upstream of GFP ORF. The most efficiently working target sites by EBNA1 TALEN were as follows; left TALEN (E1TN_L) 19 bases target sequence is 5'-TAG GAC AGA AGG AAG ACT C-3' and right TALEN (E1TN R) 19 base target sequence is 5'-TCC ACT GCC GCC GGA GCC C-3'. In human, no such 19 base sequence with 100% identical to EBNA1 are found.

**Constitutive RFP indicates transfection efficiency while EGFP expression implies that a potential target site was disrupted.**

EGFP only becomes expressed when the E1TN pair mediates in-frame correction from the out-of-frame site at upstream of GFP ORF. The most efficiently working target sites by EBNA1 TALEN were as follows; left TALEN (E1TN_L) 19 bases target sequence is 5'-TAG GAC AGA AGG AAG ACT C-3' and right TALEN (E1TN R) 19 base target sequence is 5'-TCC ACT GCC GCC GGA GCC C-3'. In human, no such 19 base sequence with 100% identical to EBNA1 are found. The RFP^+GFP^−EBNA1 reporter plasmid contains an EBNA1 oligo sequence, that is 5'-CTA GGA CAG AAG GAA GCC TCA ACA GGA CCA GAA GCC TCC GCC GCC AGT GGA (A)-3'.
Cell culture, transfection, sorting and selection of targeted cells, verification of gene disruption and rate of EBV genome loss upon E1TN introduction

EBNA1 gene disruption was verified by T7E1 assay as described (17, 18, 20) (detail in SI).

Spike experiments

EBV-negative BJAB cells were mixed with EBV-positive RAJI cells with at a ratio of 1:10, 1:100 and 1:1000 and transfected with a pair of TALEN plasmids (2 μg each) and RFP+/GFP- reporter plasmid (4 μg). Two days later, double positive (RFP+GFP+ cells) were sorted and plated at 10 or 10² cells/well, and the number of surviving colonies was scored. EBNA1 KO was tested by T7E1 and western blotting, whilst the identity of overgrown colonies was verified by short tandem repeats (STR) profiling. For mini-STR, FGA STR marker was amplified using primer set of forward 5'-GGCTGCAGGGCATAA CATT-3' and reverse 5'-ATCTATGACTTTGCGCTTCAGGA-3' and separated on 10% polyacrylamide/1XTAE gel. Complete DNA fingerprinting for 16 STR markers was undertaken at the Korea Cell Line Bank, a World Intellectual Property Organization (WIPO)-accredited international cell line repository in Korea (Seoul, Korea).

ACKNOWLEDGEMENTS

This study was supported by a grant from the National Research Foundation of Korea, NRF-2015 R1A2A2A01006459 granted to MSK and NRF-2014R1A1A2056910 to EKL. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No. 2015048055).

REFERENCES

1. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118, 3030-3044
2. Granato M, Feederle R, Farina A et al (2008) Deletion of Epstein-Barr virus BFLF2 leads to impaired viral DNA packaging and primary egress as well as to the production of defective viral particles. J Virol 82, 4042-4051
3. Adams A and Lindahl T (1975) Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Proc Natl Acad Sci U S A 72, 1477-1481
4. Raynaud FI, Whittaker SR, Fischer PM et al (2005) In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 11, 4875-4887
5. Henderson A, Ripley S, Heller M and Kieff E (1983) Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc Natl Acad Sci U S A 80, 1987-1991
6. Matsuo T, Heller M, Petti L, O’Shiro E and Kieff E (1984) Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA. Science 226, 1322-1325
7. Sugden B, Marsh K and Yates J (1985) A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol Cell Biol 5, 410-413
8. Yates JL, Warren N and Sugden B (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313, 812-815
9. Kang MS, Lee EK, Soni V et al (2011) Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance. J Virol 85, 2859-2868
10. Kang MS, Hung SC and Kieff E (2001) Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci U S A 98, 15233-15238
11. Nasimuzzaman M, Kuroda M, Dohno S et al (2005) Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. Mol Ther 11, 578-590
12. Yin Q and Fleming KE (2006) siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virolgy 346, 385-393
13. Miller JC, Tan S, Qiao G et al (2011) A TALE nuclelease architecture for efficient genome editing. Nat Biotechnol 29, 143-148
14. Kim SY, Song KA, Kieff E and Kang MS (2012) Small molecule and peptide-mediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization. Biochem Biophys Res Commun 424, 251-256
15. Lee EK, Kim SY, Noh KW et al (2014) Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome. Antiviral Res 104C, 73-83
16. Cohen JJ, Mocarski ES, Raab-Traub N, Corey L and Nabel GI (2013) The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine 31 Suppl 2, B194-196
17. Kim Y, Kweon J, Kim A et al (2013) A library of TAL effector nucleases spanning the human genome. Nat Biotechnol 31, 251-258
18. Sung YH, Baek IJ, Kim DH et al (2013) Knockout mice created by TALEN-mediated gene targeting. Nat Biotechnol 31, 23-24
19. Sung YH, Baek IJ, Seong JK, Kim JS and Lee HW (2012) Mouse genetics: catalogue and scissors. BMB Rep 45, 686-692
20. Molesworth SJ, Lake CM, Borza CM, Turk SM and Hutt-Fletcher LM (2000) Epstein-Barr virus protein gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J Virol 74, 6324-6332
21. Park J, Bae EK, Lee C et al (2014) Establishment and characterization of bortezomib-resistant U266 cells: constitutive activation of NF-kappaB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Rep 47, 274-279

http://bmbreports.org